论文部分内容阅读
[目的]对河南林州筛查组与对照组食管/贲门癌患者生命质量进行调查和评价,比较筛查组和对照组两组人群生命质量的差别,为“食管癌早诊早治”项目的开展提供科学依据。[方法]对2007～2009年筛查出的食管/贲门黏膜重度不典型增生及以上病变,并到河南林州肿瘤医院进行治疗的患者作为筛查组,而这3年自发去林州肿瘤医院治疗的食管/贲门黏膜重度不典型增生及以上病变的患者为对照组,其中筛查组124例,对照组98例,分别于治疗前、治疗后1个月、治疗后半年以及治疗后1年对调查对象采用自行设计的生命质量量表进行调查。采用描述性分析的方法,评价食管/贲门癌患者的生命质量情况,在不同调查时间比较两组的得分差异。[结果]筛查组在治疗前、治疗后1个月、治疗后半年以及1年生命质量平均总分均高于对照组且结果有统计学意义(P<0.05)。筛查组在治疗前、治疗后1个月、治疗后半年以及治疗后1年的总分平均为0.921±0.049、0.862±0.073、0.866±0.062和0.875±0.055,而对照组则分别为0.719±0.120、0.613±0.134、0.648±0.146和0.670±0.139。[结论]对食管癌高发地区40～69岁的高危人群进行食管/贲门癌的筛查及早诊早治对食管/贲门癌患者的生命质量大有益处。
[Objective] To investigate and evaluate the quality of life of esophagus / cardiac cancer patients in screening group and control group in Linzhou, Henan Province, and to compare the quality of life between the two groups of screening and control groups for the quality of life, "The project provides a scientific basis for carrying out. [Methods] From 2007 to 2009 screening of esophageal / cardia mucosa severe atypical hyperplasia and above lesions, and to Henan Linzhou Cancer Hospital for treatment of patients as a screening group, and these three years spontaneously to Linzhou Cancer Hospital Treatment of esophageal / cardia mucosa severe atypical hyperplasia and above lesions in patients as control group, of which 124 cases of screening group, control group 98 cases, respectively, before treatment, after treatment for 1 month, after treatment for six months and 1 year after treatment Investigate the respondents using self-designed quality of life questionnaire. Descriptive analysis was used to evaluate the quality of life of patients with esophageal / cardiac cancer, and the scores of the two groups were compared at different time points. [Results] The average scores of quality of life before screening, 1 month after treatment, 6 months after treatment and 1 year after treatment in the screening group were all higher than those in the control group (P <0.05). The total score of the screening group before treatment, 1 month after treatment, half a year after treatment and 1 year after treatment averaged 0.921 ± 0.049, 0.862 ± 0.073, 0.866 ± 0.062 and 0.875 ± 0.055 respectively, while the control group was 0.719 ± 0.613 ± 0.134, 0.648 ± 0.146 and 0.670 ± 0.139. [Conclusion] The screening of esophageal / cardiac cancer and the early diagnosis and early diagnosis of esophageal / cardiac cancer patients with high risk of esophageal cancer in 40-69 years old are of great benefit to the quality of life of patients with esophageal / cardiac cancer.